A phase III trial comparing subcutaneous and intravenous tocilizumab in patients with rheumatoid arthritis in Japan.

Trial Profile

A phase III trial comparing subcutaneous and intravenous tocilizumab in patients with rheumatoid arthritis in Japan.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Tocilizumab (Primary) ; Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms MUSASHI
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 27 Aug 2013 Results published in the Arthritis care and research.
    • 14 Nov 2012 12-week outcomes of the extension study presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top